Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients

Pharmacogenomics

Volumn 14, Issue 11, 2013, Pages 1283-1294

  Lee, Hon Kit ^a   Hu, Miao ^a   Lui, Sandra Sh ^a   Ho, Chung Shun ^a   Wong, Chun Kwok ^a   Tomlinson, Brian ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

ABCG2; pharmacogenetics; pharmacokinetics; rosuvastatin; SLCO1B1

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; DRUG METABOLITE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N DESMETHYLROSUVASTATIN; ORGANIC ANION TRANSPORTER 2; ROSUVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; COTRANSPORTER; CYP2C9 PROTEIN, HUMAN; FLUOROBENZENE; ORGANIC ANION TRANSPORTER; PYRIMIDINE DERIVATIVE; SLCO1B1 PROTEIN, HUMAN; SODIUM-BILE ACID COTRANSPORTER; SULFONAMIDE; TUMOR PROTEIN; UNSPECIFIC MONOOXYGENASE;

ABCG2 GENE; ADULT; ARTICLE; BODY WEIGHT; CHINESE; CHOLESTEROL BLOOD LEVEL; CYP2C19 GENE; CYP2C9 GENE; DEMETHYLATION; DRUG BLOOD LEVEL; EVENING DOSAGE; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; SEX DIFFERENCE; SLC10A1 GENE; SLCO1B1 GENE; TANDEM MASS SPECTROMETRY; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; DRUG EFFECTS; GENETIC ASSOCIATION; GENETICS; LIPID METABOLISM; MIDDLE AGED;

ADULT; AGED; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; ATP-BINDING CASSETTE TRANSPORTERS; CHOLESTEROL, LDL; CYTOCHROME P-450 CYP2C9; FEMALE; FLUOROBENZENES; GENETIC ASSOCIATION STUDIES; HUMANS; LIPID METABOLISM; MALE; MIDDLE AGED; NEOPLASM PROTEINS; ORGANIC ANION TRANSPORTERS; ORGANIC ANION TRANSPORTERS, SODIUM-DEPENDENT; PYRIMIDINES; SULFONAMIDES; SYMPORTERS;

EID: 84882247785     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.115     Document Type: Article

References (32)

1. Arai H, Yamamoto A, Matsuzawa Y et al. Polymorphisms in four genes related to triglyceride and HDL-cholesterol levels in the general Japanese population in 2000. J. Atheroscler. Thromb. 12(5), 240-250 (2005).
2. Lee E, Ryan S, Birmingham B et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin. Pharmacol. Ther. 78(4), 330-341 (2005).
3. Tzeng TB, Schneck DW, Birmingham BK et al. Population pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemia. Curr. Med. Res. Opin. 24(9), 2575-2585 (2008).
4. White CM. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J. Clin. Pharmacol. 42(9), 963-970 (2002).
5. Hu M, To KK, Mak VW, Tomlinson B. The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins. Expert Opin. Drug Metab. Toxicol. 7(1), 49-62 (2011).
6. Romaine SP, Bailey KM, Hall AS, Balmforth AJ. The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics J. 10(1), 1-11 (2009).
7. Ho RH, Tirona RG, Leake BF et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130(6), 1793-1806 (2006).
8. Choi JH, Lee MG, Cho JY, Lee JE, Kim KH, Park K. Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. Clin. Pharmacol. Ther. 83(2), 251-257 (2008).
9. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin. Pharmacol. Ther. 82(6), 726-733 (2007).
10. Zhang W, Yu BN, He YJ et al. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin. Chim. Acta 373(1-2), 99-103 (2006).
11. Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin. Pharmacol. Ther. 86(2), 197-203 (2009).
12. Tomlinson B, Hu M, Lee VW et al. ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clin. Pharmacol. Ther. 87(5), 558-562 (2010).
13. Hu M, Lui SS, Mak VW et al. Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients. Pharmacogenet. Genomics 20(10), 634-637 (2010).
14. Chasman DI, Giulianini F, Macfadyen J, Barratt BJ, Nyberg F, Ridker PM. Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Circ. Cardiovasc. Genet. 5(2), 257-264 (2012).
15. Telbisz A, Muller M, Ozvegy-Laczka C et al. Membrane cholesterol selectively modulates the activity of the human ABCG2 multidrug transporter. Biochim. Biophys. Acta 1768(11), 2698-2713 (2007).
16. Rodrigues AC, Hirata MH, Hirata RD. Impact of cholesterol on ABC and SLC transporters expression and function and its role in disposition variability to lipid-lowering drugs. Pharmacogenomics 10(6), 1007-1016 (2009).
17. Lee HK, Ho CS, Hu M, Tomlinson B, Wong CK. Development and validation of a sensitive method for simultaneous determination of rosuvastatin and N-desmethyl rosuvastatin in human plasma using liquid chromatography/negative electrospray ionization/tandem mass spectrometry. Biomed. Chromatogr. doi:10.1002/bmc.2944 (2013) (Epub ahead of print).
18. Hu M, Mak VWL, Chu TTY, Waye MMY, Tomlinson B. Pharmacogenetics of HMG-CoA reductase inhibitors: optimizing the prevention of coronary heart disease. Curr. Pharmacogenomics Pers. Med. 7(1), 1-26 (2009).
19. Zamber CP, Lamba JK, Yasuda K et al. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 13(1), 19-28 (2003).
20. Morisaki K, Robey RW, Ozvegy-Laczka C et al. Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother. Pharmacol. 56(2), 161-172 (2005).
21. Telbisz A, Ozvegy-Laczka C, Hegedus T, Varadi A, Sarkadi B. Effects of the lipid environment, cholesterol and bile acids on the function of the purified and reconstituted human ABCG2 protein. Biochem. J. 450(2), 387-395 (2013).
22. Merino G, van Herwaarden AE, Wagenaar E, Jonker JW, Schinkel AH. Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver. Mol. Pharmacol. 67(5), 1765-1771 (2005).
23. Martin PD, Dane AL, Nwose OM, Schneck DW, Warwick MJ. No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor. J. Clin. Pharmacol. 42(10), 1116-1121 (2002).
24. Konig J, Cui Y, Nies AT, Keppler D. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am. J. Physiol. Gastrointest. Liver Physiol. 278(1), G156-G164 (2000).
25. Iusuf D, van Esch A, Hobbs M et al. Murine Oatp1a/1b uptake transporters control rosuvastatin systemic exposure without affecting its apparent liver exposure. Mol. Pharmacol. 83(5), 919-929 (2013).
26. Watanabe T, Kusuhara H, Maeda K, Shitara Y, Sugiyama Y. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J. Pharmacol. Exp. Ther. 328(2), 652-662 (2009).
27. Choi MK, Shin HJ, Choi YL, Deng JW, Shin JG, Song IS. Differential effect of genetic variants of Na(+)-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors. Xenobiotica 41(1), 24-34 (2011).
28. Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin. Pharmacol. Ther. 80(4), 356-366 (2006).
29. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br. J. Pharmacol. 158(3), 693-705 (2009).
30. Weiss J, Sauer A, Divac N et al. Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm. Drug Dispos. 31(2-3), 150-161 (2010).
31. Sakaeda T, Fujino H, Komoto C et al. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm. Res. 23(3), 506-512 (2006).
32. Macwan JS, Ionita IA, Akhlaghi F. A simple assay for the simultaneous determination of rosuvastatin acid, rosuvastatin-5S-lactone, and N-desmethyl rosuvastatin in human plasma using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Anal. Bioanal. Chem. 402(3), 1217-1227 (2012).